Alkermes' Alixorexton Shows Sustained Efficacy in Narcolepsy Long-Term Study
Event summary
- Alkermes' alixorexton demonstrated sustained improvement in wakefulness and patient-reported outcomes for up to nine months in adults with narcolepsy type 1 and type 2.
- Interim analysis of the long-term extension study showed clinically meaningful improvements on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS).
- Alixorexton was generally safe and well tolerated across all doses tested, with no serious treatment-emergent adverse events reported.
- The ongoing LTE study remains open for enrollment for participants completing phase 2 and phase 3 studies of alixorexton.
The big picture
Alkermes' positive long-term data for alixorexton comes as the biopharmaceutical industry increasingly focuses on targeted therapies for rare neurological disorders. The sustained efficacy across multiple dimensions of narcolepsy underscores the potential of orexin 2 receptor agonists to address unmet needs in hypersomnolence disorders. Alkermes' strategic focus on neuroscience positions it to capitalize on growing demand for innovative treatments in this space.
What we're watching
- Regulatory Pathway
- Whether the sustained efficacy data will accelerate alixorexton's regulatory approval process for narcolepsy type 1 and type 2.
- Market Differentiation
- How alixorexton's dosing flexibility and broad efficacy profile will position it against existing narcolepsy treatments.
- Pipeline Progress
- The pace at which Alkermes advances the phase 3 Brilliance Studies and completes the Vibrance-3 phase 2 study in idiopathic hypersomnia.